转移性结直肠癌一线诱导治疗后卡培他滨联合贝伐珠单抗维持治疗的成本效果分析
基于CAIRO3研究(n=558)的决策分析Markov模型,评估卡培他滨联合贝伐珠单抗(CAP-B)维持治疗对比观察的成本效果。CAP-B维持较观察获得0.21个质量调整生命年(QALY)和0.18个生命年(LY),平均成本增加36845欧元,ICER为每QALY 175452欧元(每LY 204694欧元)。在诱导治疗后达到完全或部分缓解的患者中,ICER为每QALY 149300欧元。作者认为尽管癌症治疗的成本效果阈值尚无共识,CAP-B维持可能不被认为是具有成本效果的。
要点
- CAP-B维持较观察获得0.21个QALY和0.18个LY,平均成本增加36845欧元。
- 总体ICER为每QALY 175452欧元(每LY 204694欧元)。
- 完全或部分缓解患者中ICER为每QALY 149300欧元。
核心结论
- CAP-B维持治疗较观察改善了以QALY和LY衡量的健康结局,但也带来相关成本增加。
- 尽管癌症治疗的成本效果阈值尚无共识,CAP-B维持可能不被认为是具有成本效果的。
研究设计与样本
- 基于CAIRO3研究(n=558)结果的决策分析Markov模型,评估CAP-B维持对比观察的成本效果。
- 对诱导治疗后达到完全或部分缓解的患者进行额外分析。
- 主要结局为增量成本效果比(ICER),定义为每获得一个生命年(LY)和每获得一个质量调整生命年(QALY)的额外成本,QALY基于EQ-5D问卷和文献计算。
- 进行单因素敏感性分析评估输入参数对ICER的影响,概率敏感性分析代表模型参数的不确定性。
主要发现
- CAP-B维持较观察获得0.21个QALY(0.18个LY),平均成本增加36845欧元。
- 总体ICER为每QALY 175452欧元(每LY 204694欧元)。
- CAP-B维持与观察之间健康相关生活质量差异的变化对ICER影响最大。
- 在卡培他滨、奥沙利铂、贝伐珠单抗诱导治疗后达到完全或部分缓解的患者中,ICER为每QALY 149300欧元。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: Capecitabine and bevacizumab (CAP-B) maintenance therapy has shown to be more effective compared with observation in metastatic colorectal cancer patients achieving stable disease or better after six cycles of first-line capecitabine, oxaliplatin, bevacizumab treatment in terms of progression-free survival. We evaluated the cost-effectiveness of CAP-B maintenance treatment. METHODS: Decision analysis with Markov modelling to evaluate the cost-effectiveness of CAP-B maintenance compared with observation was performed based on CAIRO3 study results (n = 558). An additional analysis was performed in patients with complete or partial response. The primary outcomes were the incremental cost-effectiveness ratio (ICER) defined as the additional cost per life year (LY) and quality-adjusted life years (QALY) gained, calculated from EQ-5D questionnaires and literature and LYs gained. Univariable sensitivity analysis was performed to assess the influence of input parameters on the ICER, and a probabilistic sensitivity analysis represents uncertainty in model parameters. RESULTS: CAP-B maintenance compared with observation resulted in 0.21 QALYs (0.18LYs) gained at a mean cost increase of €36,845, yielding an ICER of €175,452 per QALY (€204,694 per LY). Varying the difference in health-related quality of life between CAP-B maintenance and observation influenced the ICER most. For patients achieving complete or partial response on capecitabine, oxaliplatin, bevacizumab induction treatment, an ICER of €149,300 per QALY was calculated. CONCLUSION: CAP-B maintenance results in improved health outcomes measured in QALYs and LYs compared with observation, but also in a relevant increase in costs. Despite the fact that there is no consensus on cost-effectiveness thresholds in cancer treatment, CAP-B maintenance may not be considered cost-effective.
引用
- Franken MD, van Rooijen EM, May AM, et al. Cost-effectiveness of capecitabine and bevacizumab maintenance treatment after first-line induction treatment in metastatic colorectal cancer. Eur J Cancer. 2017. PMID: 28237866. doi:10.1016/j.ejca.2017.01.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。